U.S. Tuberculosis Diagnostics - Industry Report

The U.S. tuberculosis diagnostics market size accounted for USD 594.53 million in 2024 and is expected to exceed around USD 1,025.21 million by 2034, growing at a CAGR of 5.6% from 2024 to 2034.

U.S. Tuberculosis Diagnostics Market Report Highlights

• By test type, the detection of the latent infection (skin test & IGRA) test type segment dominated the U.S. tuberculosis diagnostics market in 2024.
• By test type, the detection of the Drug Resistance (DST) test type segment is expected to grow fastest during the forecast period.
• By end-use, the diagnostic laboratories end-use segment dominated the U.S. tuberculosis diagnostics market in 2024.
• By end-use, the hospitals and clinics end-user segment is anticipated to grow at a significant growth over the forecast period.

The U.S. tuberculosis diagnostics market refers to the production, distribution, and application of this tuberculosis diagnosis, which includes physical examination, tests for TB infection, chest X-ray, and laboratory tests to detect the presence of Mycobacterium tuberculosis. Tuberculosis is an infectious disease caused by bacteria that affects the lungs. It spreads through the air when affected people cough, sneeze, or spit. The disease is preventable and curable. Tuberculosis blood tests use a blood sample to find out if you are infected with the pathogen Mycobacterium tuberculosis. It is an infectious disease caused by bacteria that may affect the lungs. Sputum culture is the gold standard for Tuberculosis diagnosis and has excellent sensitivity and specificity. Although chest X-ray remains the basic imaging modality for pulmonary tuberculosis, nuclear medicine techniques, including computed tomography/positron emission tomography, magnetic resonance imaging, and computed tomography, are highly helpful in assessing both pulmonary and extrapulmonary tuberculosis. 

The rising prevalence of tuberculosis is driving the growth of the U.S. tuberculosis diagnostics market. The disease is spread by releasing tiny droplets that carry the bacteria through the air. This can happen when normal interactions such as speaking, coughing, or sneezing occur. The disease is diagnosed mainly through Interferon Gamma Release Assay (IGRA) testing.

The diagnostics can show whether you have the germs in your body and need more testing. It does not show if you have an inactive infection or active disease. A complete blood count is an important test for tuberculosis. A routine complete blood count checks for levels of ten components of every major cell in your blood- platelets, red blood cells, and white blood cells. This test measures important components, including hematocrit, hemoglobin, and red blood cell count.

Growing awareness about the disease contributes to the growth of the U.S. tuberculosis diagnostics market. Knowledge of effective preventive measures and financial support can help people suffering from such diseases manage their conditions. Growing awareness about the disease is important in early diagnosis, ultimately contributing to better management and treatment. Another important benefit of being aware of the available treatment facilities, in turn, helps you stay away from unnecessary depression.

Health awareness campaigns educate communities, enhance public health, prevent diseases, and promote wellness. With the right public information dissemination strategies, healthcare awareness can extend to patient care in settings other than points of contact with healthcare providers and bolster social support within marginalized communities. This growing awareness and more frequent testing is helping catch cases earlier and contributing to growth in the sector.

Rising demand for rapid and accurate diagnostic tests contributes to the growth of the U.S. tuberculosis diagnostics market. Early detection and fast turnaround times are important to help minimize suffering and limit the spread of disease. This will enhance the odds of the patient making a full recovery. If a rapid, sensitive, and specific point-of-care test is available, diagnosing a patient in the very early stages of the infection is possible. This may even be before the patient becomes symptomatic or begins to infect others.

Rapid diagnostic tests for infectious diseases, with less than two hours turnaround times, are promising tools that enhance patient care. Programs such as antimicrobial stewardship and infection prevention in the emergency department setting are crucial to curb the spread of tuberculosis. These programs require little to no special equipment and are easy to implement and follow for patients and those who fear exposure to the disease. 

The emergence of artificial intelligence provides a more convenient and rapid way to predict the efficacy of tuberculosis, mainly in pulmonary tuberculosis. By integrating image information or other clinical data, AI can be extensively employed for the screening, diagnosis, and prognostication of many diseases. AI is also helpful in the differential diagnosis of pneumonia and tuberculosis, with diagnostic accuracy as high as 97.7%. AI systems can monitor and analyze data in real time, providing an instantaneous and comprehensive view of lab processes. AI can predict potential issues before they occur. These factors help the growth of the U.S. tuberculosis diagnostics market.

Due to several important trends, the market for tuberculosis diagnostics is expected to grow in the United States in the coming years. Government agencies, such as the Centers for Disease Control and Prevention (CDC), have launched initiatives around the clinical testing and diagnosis of tuberculosis, including targeted testing. The CDC is also assisting in initiatives such as the U.S. Preventive Services Task Force (USPSTF), which identifies vulnerable groups of people, such as those with HIV and diabetes mellitus, and tests them routinely for the disease.